JAMA 4 2026 Cost-Effectiveness of ApoB, Non–HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy.

This study utilized computer simulations to evaluate whether monitoring Apolipoprotein B (apoB) is a more efficient and affordable way to prevent heart disease compared to traditional cholesterol markers. Researchers found that while tracking non-HDL cholesterol saves money over standard LDL-C methods, prioritizing an apoB goal provides the greatest health benefits by extending life expectancy. Although this specific blood test leads to higher long-term treatment costs, it remains highly cost-effectivebecause it significantly improves the quality and duration of a patient's life. Ultimately, the paper suggests that shifting medical focus toward apoB as a primary marker for lipid-lowering therapy could optimize population health outcomes within reasonable budget limits.